Business
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
PONTE VEDRA, Fla., March 04, 2025--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT) to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2289,"height":530,"url":"https://media.zenfs.com/en/business-wire.com/c7b3124cdef6dd68fcaf1b0c9b381fc8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bohmzWlTSM.8UgcVEJE3ng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c7b3124cdef6dd68fcaf1b0c9b381fc8","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/krYfqgzHoaJVUoCG.lXSCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c7b3124cdef6dd68fcaf1b0c9b381fc8","width":1200,"height":278}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients","length":169,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":169,"olType":false},{"type":"text","content":"PONTE VEDRA, Fla., March 04, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT) to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.","length":498,"tagName":"p"},{"type":"text","content":"Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3™ trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise.","length":412,"tagName":"p"},{"type":"text","content":""We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enroll...